Product Description
Mechanisms of Action: ERBB2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Holding
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for B003](https://pryzm-maps.s3.us-west-2.amazonaws.com/12current_maps.png)
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
B003-101 | P1 |
Completed |
Breast Cancer |
2023-01-13 |
34% |
CTR20190405 | P1 |
Recruiting |
Breast Cancer |
None |